title: [Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
abstract: BACKGROUND
  Percutaneous transluminal coronary angioplasty (PTCA) of chronic total coronary artery occlusions is associated with very high restenosis and reocclusion rates. Coronary stenting has been proposed as a means of improving outcome. However, the Wiktor device for chronic coronary occlusion has never been tested in a large patient sample. This study reports the first multicenter experience with the Wiktor stent for treatment of chronic occlusions.
  
  
  METHODS
  From January 1993 to December 1996, 89 consecutive patients with 91 chronic occlusions underwent Wiktor stent implantation after successful PTCA. Post-stenting regimen consisted of coumadin plus aspirin in the first 49 (55%) patients and aspirin plus ticlopidine in the following 40 (45%).
  
  
  RESULTS
  Stenting was successful in 87 (98%) patients. At 1 month, 6% of patients had subacute stent thrombosis, 1% access-site complications and 3% major bleeding events. Stent thrombosis showed a univariate association with coumadin therapy (p = 0.009). Angiographic follow-up was obtained in 93% of 82 eligible patients. Restenosis rate was 32%, including 4% reocclusions. Through multiple logistic regression analysis, restenosis was independently associated with multiple stents (odds ratio-OR = 27.67, 95% confidence interval-CI = 4.25 to 79.95, p = 0.0008) and increasing values of occlusion length (OR = 1.23, 95% CI = 1.09 to 1.39, p = 0.001). Freedom from death, myocardial infarction or stented vessel revascularization was 87 and 72% at one and three years, respectively.
  
  
  CONCLUSIONS
  Short- and long-term clinical and angiographic outcomes are favorable in patients undergoing Wiktor stent implantation for chronic coronary occlusion. Further technical refinements are needed to reduce restenosis rate in patients with long lesions and multiple stents.
authors.affiliation: Dipartimento di Cardiologia, Ospedale San Raffaele, Milano.
authors.forename: A
authors.initials: A
authors.lastname: Anzuini
authors.forename: S
authors.initials: S
authors.lastname: Rosanio
authors.forename: V
authors.initials: V
authors.lastname: Legrand
authors.forename: M
authors.initials: M
authors.lastname: Tocchi
authors.forename: R
authors.initials: R
authors.lastname: Coppi
authors.forename: G
authors.initials: G
authors.lastname: Marazzi
authors.forename: G
authors.initials: G
authors.lastname: Vicedomini
authors.forename: P
authors.initials: P
authors.lastname: Pagnotta
authors.forename: M
authors.initials: M
authors.lastname: Montorfano
authors.forename: H
authors.initials: H
authors.lastname: Bonnier
authors.forename: I
authors.initials: I
authors.lastname: Sheiban
authors.forename: H E
authors.initials: HE
authors.lastname: Kulbertus
authors.forename: S L
authors.initials: SL
authors.lastname: Chierchia
mesh_terms: D000704:Analysis of Variance; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002908:Chronic Disease; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012008:Recurrence; D015607:Stents / Q000009:adverse effects; D013988:Ticlopidine / Q000627:therapeutic use; D013997:Time Factors; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014859:Warfarin; D013988:Ticlopidine; D001241:Aspirin